Advertisement

Mesothelioma and Pseudomyxoma peritonei: Incidence, Etiology, Diagnosis

  • Amir G. Abdulaev
  • Boris E. Polotskiy
  • Mikhail M. Davydov
Chapter

Abstract

Pseudomyxoma peritonei and peritoneal are similar in predominant affection of peritoneum, low frequency of lymphogenic and hematogenic metastasis and lack of efficient treatment methods. Pseudomyxoma peritonei is a neoplastic disease that is characterized by mucinous carcinomatosis of the peritoneum and it always arises as a result of another tumor of various differentiation grades. Pseudomyxoma peritonei is a rare disease that shows significant difficulties for pathologic differentiation diagnosis from other tumors with intraperitoneal dissemination. Peritoneal mesothelioma (PM) is a primary peritoneal tumor with increasing incidence worldwide. Different histological subtypes with different tumor aggressiveness have been described. Accurate histopathological analysis of an adequate biopsy specimen is needed when a primary peritoneal tumor is suspected. The pattern of spread of PM is predominantly expansive more than infiltrative or haematological.

Keywords

Peritoneal mesothelioma Pseudomyxoma peritonei Incidence Etiology Diagnosis 

References

  1. 1.
    Guo AT, Song X, Wei LX, Zhao P (2011) Histological origin of pseudomyxoma peritonei in Chinese women: clinicopathology and immunohistochemistry. World J Gastroenterol 17(30):3531–3537CrossRefGoogle Scholar
  2. 2.
    Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH (2003) Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol 27:1089–1103CrossRefGoogle Scholar
  3. 3.
    Moran BJ, Cecil TD (2003) The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am 12:585–603CrossRefGoogle Scholar
  4. 4.
    Nakakura EK (2012) Pseudomyxoma peritonei: more questions than answers. J Clin Oncol 30(20):2429–2430CrossRefGoogle Scholar
  5. 5.
    Carr NJ, Emory TS, Sobin LH (2002) Epithelial neoplasms of the appendix and colorectum: an analysis of cell proliferation, apaptosis and expression of p53, CD44, bcl-2. Arch Pathol Lab Med 126:837–841PubMedGoogle Scholar
  6. 6.
    Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM (1995) Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinoma¬tosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to pseudomyxoma peritonei. Am J Surg Pathol 19:1390–1408CrossRefGoogle Scholar
  7. 7.
    Carr NJ, Emory TS, Sobin LH (2003) Epithelial neoplasms of the appendix. In: Odze RD, Goldblum RG (eds) Surgical pathology of the GI tract, liver, biliary tract and pancreas. IARC Press, Lyon, pp 645–647Google Scholar
  8. 8.
    Imaoka H, Yamao K, Salem AA, Mizuno N, Takahashi K, Sawaki A, Isaka T, Okamoto Y, Yanagisawa A, Shimizu Y (2006) Pseudomyxoma peritonei caused by acute pancreatitis in intraductal papillary mucinous carcinoma of the pancreas. Pancreas 32(2):223–224CrossRefGoogle Scholar
  9. 9.
    Hawes D, Robinson R, Wira R (1991) Pseudomyxoma peritonei from metastatic colloid carcinoma of the breast. Gastrointest Radiol 16:80–82CrossRefGoogle Scholar
  10. 10.
    Kahn MA, Demopoulos RI (1992) Mucinous ovarian tumors with pseudomyxoma peritonei: a clinicopathological study. Int J Gynecol Pathol 11:15–23CrossRefGoogle Scholar
  11. 11.
    Ronnett BM, Seidman JD (2003) Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol 27:650–657CrossRefGoogle Scholar
  12. 12.
    Dabbs DJ (ed) (2010) Diagnostic immunohistochemistry: theranostic and genomic applications. Saunders, Philadelphia, pp 511–648Google Scholar
  13. 13.
    Vang R, Ronnett BM (2009) Metastatic and miscellaneous tumors of the ovary. In: Nucci MR, Oliva E (eds) Gynecologic pathology. Elsevier, Edinburgh, pp 539–564CrossRefGoogle Scholar
  14. 14.
    Bahrami A, Luan DT, Jae YR (2008) Undifferentiated tumor: true identity by immunohistochemistry. Arch Pathol Lab Med 132:326–348PubMedGoogle Scholar
  15. 15.
    Terada T (2013) An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: expression of EMA, CEA, CA19-9, CDX-2, p53, Ki-67 antigen, TTF-1 and p63 in normal mucosa and in 42 cases. Int J Clin Exp Pathol 6(4):630–638PubMedPubMedCentralGoogle Scholar
  16. 16.
    Shin JH, Bae JH, Lee A, Jung CK, Yim HW, Park JS, Lee KY (2010) CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J Clin Oncol 40(3):208–213CrossRefGoogle Scholar
  17. 17.
    Ferreira CR, Carvalho JP, Soares FA, Siqueira SA, Carvalho FM (2008) Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors. Int J Gynecol Cancer 18(1):59–65CrossRefGoogle Scholar
  18. 18.
    Szych C, Staebler A, Connolly DC, Wu R, Cho KR, Ronnett BM (1999) Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. Am J Pathol 154(6):1849–1855CrossRefGoogle Scholar
  19. 19.
    Taflampas P, Dayal S, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ (2014) Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: analysis of 519 patients. Eur J Surg Oncol 40(5):515–520CrossRefGoogle Scholar
  20. 20.
    Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M (2009) Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg 249(2):243–249CrossRefGoogle Scholar
  21. 21.
    Chang MS, Byeon SJ, Yoon SO, Kim BH, Lee HS, Kang GH, Kim WH, Park KJ (2012) Leptin, MUC2 and mTOR in appendiceal mucinous neoplasms. Pathobiology 79(1):45–53CrossRefGoogle Scholar
  22. 22.
    Sitzmann JV, Wiebke EA (2013) Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer. JAMA Surg 148(3):285–291CrossRefGoogle Scholar
  23. 23.
    Taggart MW, Galbincea J, Mansfield PF, Fournier KF, Royal RE, Overman MJ, Rashid A, Abraham SC (2013) High-level microsatellite instability in appendiceal carcinomas. Am J Surg Pathol 37(8):1192–1200CrossRefGoogle Scholar
  24. 24.
    Shetty S, Thomas P, Ramanan B, Sharma P, Govindarajan V, Loggie B (2013) Kras mutations and p53 overexpression in pseudomyxoma peritonei: association withphenotype and prognosis. J Surg Res 180(1):97–103CrossRefGoogle Scholar
  25. 25.
    Nishikawa G, Sekine S, Ogawa R, Matsubara A, Mori T, Taniguchi H, Kushima R, Hiraoka N, Tsuta K, Tsuda H, Kanai Y (2013) Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br J Cancer 108(4):951–958CrossRefGoogle Scholar
  26. 26.
    Mohamed F, Gething S, Haiba M, Brun EA, Sugarbaker PH (2004) Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process. J Surg Oncol 86(1):10–15CrossRefGoogle Scholar
  27. 27.
    van Ruth S, Acherman YI, van de Vijver MJ, Hart AA, Verwaal VJ, Zoetmulder FA (2003) Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol 29(8):682–688CrossRefGoogle Scholar
  28. 28.
    Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, Gavazzi C, Laterza B, Deraco M (2008) Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 15(2):526–534CrossRefGoogle Scholar
  29. 29.
    Pulighe F, Paliogiannis P, Cossu A, Palmieri G, Colombino M, Scognamillo F, Trignano M (2013) Molecular analysis of appendiceal mucinous cystadenoma and rectal adenocarcinoma in a patient with urothelial carcinoma: a case report. J Med Case Rep 7(1):170CrossRefGoogle Scholar
  30. 30.
    Zou Y, Wang F, Liu FY, Huang MZ, Li W, Yuan XQ, Huang OP, He M (2013) RNF43 RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer. Gene 531(1):112–116CrossRefGoogle Scholar
  31. 31.
    Green FL, Page DL, Fleming ID et al (2002) AJCC cancer staging handbook. From: AJCC cancer staging manual, 6th edn. Springer, New York, pp 205–209CrossRefGoogle Scholar
  32. 32.
    Gatalica Z, Loggie B (2006) COX-2 expression in pseudomyxoma peritonei. Cancer Lett 244(1):86–90CrossRefGoogle Scholar
  33. 33.
    De Pangher Manzini V (2005) Malignant peritoneal mesothelioma. Tumori 91:1–5PubMedGoogle Scholar
  34. 34.
    Friedberg JS (2001) Chapter 56 pleura: anatomy, physiology and disorders. In: Norton JF, Bollinger RR, Chang AE et al (eds) Surgery: basic science and clinical evidence. Springer, New York, pp 1243–1264CrossRefGoogle Scholar
  35. 35.
    Boylon AM, Broaddus CV (2005) Tumors of the peura. In: Mason RJ, Broaddus VC, Murray JF et al (eds) Textbook of respiratory medicine, 4th edn. Elsevier Saunders, PhiladelphiaGoogle Scholar
  36. 36.
    Nepomnyashchaya EM, Bosenko SP (2001) Malignant pleural mesothelioma. Pulmonology 1:65–68Google Scholar
  37. 37.
    Aisner J, Wiernik PN (1978) Malignant mesothelioma: current status and future prospects. Chest 74:438–444PubMedGoogle Scholar
  38. 38.
    Welch LS, Acherman YIZ, Haile E et al (2005) Asbestos and peritoneal mesothelioma among college-educated men. Int J Occup Environ Health 11:254–258CrossRefGoogle Scholar
  39. 39.
    Yang H, Bocchetta M, Kroczynska B et al (2006) TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci 103:10397–10402CrossRefGoogle Scholar
  40. 40.
    Shatos MA, Doherty JM, Marsh JP et al (1987) Prevention of asbestosinduced cell death in rat lung fibroblasts and alveolar macrophages by scavengers of active oxygen species. Environ Res 44:103–116CrossRefGoogle Scholar
  41. 41.
    Moyer VD, Cistulli CA, Vaslet CA et al (1994) Oxygen radicals and asbestos carcinogenesis. Environ Health Perspect 102(Suppl 10):131–136CrossRefGoogle Scholar
  42. 42.
    Ault JG, Cole RW, Jensen CG et al (1995) Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells. Cancer Res 55:792–798PubMedGoogle Scholar
  43. 43.
    Topov J, Kolev K (1987) Cytology of experimental mesotheliomas induced with crocidolite asbestos. Acta Cytol 31:369–373PubMedGoogle Scholar
  44. 44.
    Craighead JE, Akley NJ, Gould LB et al (1987) Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats. Am J Pathol 129:448–462PubMedPubMedCentralGoogle Scholar
  45. 45.
    Aung W, Hasegawa S, Furukawa T et al (2007) Potential role of ferritin heavy chain in oxidative stress and apoptosis in human mesothelial and mesothelioma cells: implications for asbestos-induced oncogenesis. Carcinogenesis 28:2047–2052CrossRefGoogle Scholar
  46. 46.
    Kamp DW, Israbian VA, Preusen SE et al (1995) Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of ironcatalyzed free radicals. Am J Phys 268:471–480Google Scholar
  47. 47.
    Kashansky SV, Shaburov AP (2005) Pleural mesothelioma and asbestos exposure. Mater. XVII Sverdlovsk region. Conference on oncologists. Ekaterinburg, pp. 273–276; Kogan FM (1997) White book on white asbestos (chrysotile). Ekaterinburg 71Google Scholar
  48. 48.
    Vasilyeva LA, Pylev LN, Pivovarova LN et al (1991) Carcinogenic and fibrogenic activity of synthetic amphibole asbestos with different chemical structure. Exp Oncol 13:12–15Google Scholar
  49. 49.
    Baris YI (1981) Malignant mesothelioma and radiological chest abnormalities in two villages in Central Turkey. An epidemiological and environmental investigations. Lancet 1:984–987CrossRefGoogle Scholar
  50. 50.
    Belitsky GA (2006) Chemical carcinogenesis. Probl Clin Med 1(5):10–15Google Scholar
  51. 51.
    Vilchez RA, Kozinetz CA, Arrington AS et al (2003) Simian virus 40 in human cancers. Am J Med 114:675–684CrossRefGoogle Scholar
  52. 52.
    Carbone M, Fisher S, Powers A et al (1999) New molecular and epidemiological issues in mesothelioma: role of SV 40. J Cell Physiol 180:167–172CrossRefGoogle Scholar
  53. 53.
    Carbone M, Pass HI, Rizzo P et al (1994) Simian virus 40 large—tantigen binds p 53 in human mesotheliomas. Nat Med 3:908–912CrossRefGoogle Scholar
  54. 54.
    Mok SC, Schorge JO, Weich WR et al (2003) Peritoneal tumours. In: Tavassoli FA, Devilee P (eds) World Health Organization classification of tumours. Pathology & genetics of tumours of breast and female genital organs. IARC Press, Lyon, pp 197–202Google Scholar
  55. 55.
    Weiss SW, Goldblum JR (eds) (2008) Enzinger and Weiss’s soft tissue tumors, 5th edn. Mosby Elsevier, Philadelphia, pp 789–817Google Scholar
  56. 56.
    Clement PB, Young RH (2010) The peritoneum. In: Mills SE (ed) Sternberg’s diagnostic surgical pathology, 5th edn. Lippincott Williams & Wilkins, pp 2393–2412Google Scholar
  57. 57.
    Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA et al (2005) Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 7(1):40–46CrossRefGoogle Scholar
  58. 58.
    Foster JM, Radhakrishna U, Govindarajan V, Carreau JH, Gatalica Z, Sharma P et al (2010) Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World J Surg Oncol 8:88CrossRefGoogle Scholar
  59. 59.
    Enomoto Y, Kasai T, Takeda M, Takano M, Morita K, Kadota E et al (2012) A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma. Pathol Int 62(4):226–231CrossRefGoogle Scholar
  60. 60.
    Kalra N, Ashai A, Xi L, Zhang J, Avital I, Raffeld M et al (2012) Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors. Oncol Rep 27(6):1794–1800PubMedPubMedCentralGoogle Scholar
  61. 61.
    López-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG (2009) Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 29(15):4235–4249CrossRefGoogle Scholar
  62. 62.
    Turner K, Varghese S, Alexander HR Jr (2012) Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Cancer Netw 10(1):49–57CrossRefGoogle Scholar
  63. 63.
    Ribeiro C, Campelos S, Moura CS, Machado JC, Justino A, Parente B (2013) Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation. Ann Oncol 24(8):2147–2150CrossRefGoogle Scholar
  64. 64.
    Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43(10):1022–1025CrossRefGoogle Scholar
  65. 65.
    Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT et al (2009) Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 133(8):1317–1331PubMedGoogle Scholar
  66. 66.
    Marchevsky AM (2008) Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med 132(3):397–401PubMedGoogle Scholar
  67. 67.
    Pillai K, Pourgholami MH, Chua TC, Morris DL (2013) Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. Am J Cancer Res 3(4):411–423PubMedPubMedCentralGoogle Scholar
  68. 68.
    Pillai K, Pourgholami MH, Chua TC, Morris DL (2013) Does the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma? Am J Cancer Res 3(3):312–322PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Amir G. Abdulaev
    • 1
  • Boris E. Polotskiy
    • 1
  • Mikhail M. Davydov
    • 1
  1. 1.Oncologist and Surgeon Thoracic Research DepartmentN.N. Blokhin National Medical Research CenterMoscowRussia

Personalised recommendations